Table 1.
Baseline characteristics of the entire study population (n=1032) and divided into derivation and validation cohorts (n=516 each).
| Overall (N=1032) |
Derivation (N=516) |
Validation (N=516) |
p | |
|---|---|---|---|---|
| Age | 67.9 (12.0) | 68.4 (11.5) | 67.5 (12.4) | 0.21 |
| Male | 671 (65.0%) | 353 (68.4%) | 318 (61.6%) | 0.03 |
| African American | 500 (48.4%) | 254 (49.2%) | 246 (47.7) | 0.64 |
| COPD | 227 (22.0%) | 116 (22.5%) | 111 (21.5%) | 0.76 |
| CKD | 229 (22.2%) | 112 (21.7%) | 117 (22.7%) | 0.76 |
| Diabetes | 428 (41.5%) | 206 (39.9%) | 222 (43.0%) | 0.34 |
| Ischemic Etiology | 583 (56.5%) | 294 (57.0%) | 289 (56.0%) | 0.80 |
| Stroke/TIA | 125 (12.1%) | 52 (10.1%) | 73 (14.1%) | 0.06 |
| ACE/ARB | 667 (64.6%) | 335 (64.9%) | 332 (64.3%) | 0.90 |
| Beta Blocker | 617 (59.8%) | 309 (59.9%) | 308 (59.7%) | 1.00 |
| Heart Rate, bpm | 71.1 (13.0) | 71.2 (13.6) | 71.0 (12.4) | 0.81 |
| Systolic BP, mmHg | 128.8 (23.1) | 128.5 (23.61) | 129.2 (22.7) | 0.65 |
| Creatinine, mg/dL | 1.33 (1.03) | 1.35 (1.14) | 1.30 (0.91) | 0.51 |
| NTproBNP, pmol/L | 355.2 (380.2) | 361.7 (379.2) | 348.7 (381.4) | 0.58 |
| Ejection Fraction | 36.8 (12.5) | 36.9 (12.8) | 36.8 (12.3) | 0.97 |
| MAGGIC Score | 19.0 (7.3) | 19.3 (7.3) | 18.7 (7.4) | 0.19 |
| 6MWD, m | 318 (105) | 313 (107) | 323 (103) | 0.18 |
| NYHA = 1 | 590 (57.2%) | 293 (56.8%) | 297 (57.6%) | 0.76 |
| 2 | 180 (17.4%) | 95 (18.4%) | 85 (16.5%) | |
| 3 | 119 (11.5%) | 60 (11.6%) | 59 (11.4%) | |
| 4 | 121 (11.7%) | 59 (11.4%) | 62 (12.0%) | |
| Survival (days) | 1055.7 (617.3) | 1047.6 (595.8) | 1063.8 (638.6) | 0.67 |
| Death | 256 (24.8%) | 127 (24.6%) | 129 (25.0%) | 0.94 |